<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Potential drugs and vaccines against three coronaviruses</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2"/>
    <th>SARS-CoV</th>
    <th>MERS-CoV</th>
    <th>SARS-CoV-2</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Potential virally targeted agents</td>
    <td>Potential drugs inhibiting cell entry</td>
    <td>
     <p>CP-1</p>
     <p>Griffithsin</p>
     <p>CSS-2,3,4,5</p>
    </td>
    <td>
     <p>HR2P</p>
     <p>sDPP4</p>
     <p>7D10</p>
    </td>
    <td>
     <p>EK1</p>
     <p>EK1C4</p>
     <p>Griffithsin</p>
     <p>CSS-2,3,4,5</p>
    </td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR34">34</xref>,
      <xref ref-type="bibr" rid="CR100">100</xref>,
      <xref ref-type="bibr" rid="CR111">111</xref>,
      <xref ref-type="bibr" rid="CR113">113</xref>,
      <xref ref-type="bibr" rid="CR115">115</xref>,
      <xref ref-type="bibr" rid="CR164">164</xref>,
      <xref ref-type="bibr" rid="CR165">165</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td/>
    <td>nAbs</td>
    <td>
     <p>CR3022</p>
     <p>m396</p>
     <p>80R</p>
     <p>33G4</p>
    </td>
    <td>
     <p>m336</p>
     <p>MERS-4</p>
     <p>MERS-27</p>
    </td>
    <td>CR3022</td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR160">160</xref>–
      <xref ref-type="bibr" rid="CR163">163</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td/>
    <td>Protease inhibitors</td>
    <td>
     <p>Remdesivir</p>
     <p>Ribavirin</p>
     <p>Galidesivir</p>
     <p>Lopinavir</p>
     <p>Bananins</p>
     <p>5-Hydroxychromone</p>
     <p>derivatives</p>
     <p>Disulfiram</p>
    </td>
    <td>
     <p>Favipiravir</p>
     <p>Ribavirin</p>
     <p>Penciclovir</p>
     <p>Remdesivir</p>
     <p>Lopinavir</p>
     <p>Ritonavir</p>
     <p>Darunavir</p>
    </td>
    <td>
     <p>Remdesivir</p>
     <p>Ribavirin Galidesivir</p>
     <p>Lopinavir Ritonavir</p>
     <p>Camostat Mesylate</p>
    </td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR34">34</xref>,
      <xref ref-type="bibr" rid="CR111">111</xref>,
      <xref ref-type="bibr" rid="CR121">121</xref>,
      <xref ref-type="bibr" rid="CR122">122</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td/>
    <td>Viral RNA synthesis blockers</td>
    <td/>
    <td>Remdesivir</td>
    <td/>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR117">117</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td colspan="2">
     <p>Ribavirin</p>
     <p>Galidesivir (BCX4430)</p>
    </td>
    <td>Favipiravir (T-705)</td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR14">14</xref>,
      <xref ref-type="bibr" rid="CR34">34</xref>,
      <xref ref-type="bibr" rid="CR41">41</xref>,
      <xref ref-type="bibr" rid="CR108">108</xref>,
      <xref ref-type="bibr" rid="CR115">115</xref>,
      <xref ref-type="bibr" rid="CR122">122</xref>,
      <xref ref-type="bibr" rid="CR126">126</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td/>
    <td>Other agents</td>
    <td/>
    <td>Convalescent plasma</td>
    <td/>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR108">108</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td>
     <p>Corticosteroids</p>
     <p>6-mercaptopurine-6-thioguaninet</p>
     <p>IFNα</p>
     <p>Antiviral treatments</p>
    </td>
    <td>
     <p>IFNα</p>
     <p>Antimicrobial peptides (AMPs)</p>
     <p>Mycophenolic acid</p>
     <p>Nitazoxamide</p>
     <p>Mycophenolate mofetil (MMF)</p>
    </td>
    <td/>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR14">14</xref>,
      <xref ref-type="bibr" rid="CR19">19</xref>,
      <xref ref-type="bibr" rid="CR38">38</xref>,
      <xref ref-type="bibr" rid="CR41">41</xref>,
      <xref ref-type="bibr" rid="CR59">59</xref>,
      <xref ref-type="bibr" rid="CR122">122</xref>,
      <xref ref-type="bibr" rid="CR133">133</xref>,
      <xref ref-type="bibr" rid="CR134">134</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td colspan="2">Potential host-targeted agents</td>
    <td colspan="3">Pegylated interferon alfa-2a; Pegylated interferon alfa-2b; Metformin; Glitazones; Fibrates; Sartans; Atorvastin; nutrient supplements; biologics; cellular therapies; IFNα together with immunoglobulins or thymosins;</td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR34">34</xref>,
      <xref ref-type="bibr" rid="CR39">39</xref>,
      <xref ref-type="bibr" rid="CR136">136</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td colspan="2"/>
    <td>
     <p>Cathepsin B cathepsinL</p>
     <p>Camostat</p>
    </td>
    <td/>
    <td>Chloroquine</td>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR14">14</xref>,
      <xref ref-type="bibr" rid="CR34">34</xref>,
      <xref ref-type="bibr" rid="CR100">100</xref>,
      <xref ref-type="bibr" rid="CR134">134</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td>Spike-based vaccines</td>
    <td/>
    <td>A recombinant fusion protein (designated RBD-Fc) containing 193-amino acid RBD and a human IgG1 Fc fragment</td>
    <td>Simian adenovirus vector vaccine (ChAdOx1);an Ad vector encoding MERS-CoV S1 extracellular domain (Ad5.MERS-S1);an RABV vector encoding S1 elicit antibody;RBD-based vaccines</td>
    <td/>
    <td>
     <sup>
      <xref ref-type="bibr" rid="CR61">61</xref>,
      <xref ref-type="bibr" rid="CR138">138</xref>,
      <xref ref-type="bibr" rid="CR139">139</xref>,
      <xref ref-type="bibr" rid="CR140">140</xref>
     </sup>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
